Lantern Pharma Inc.
For the period ended Dec 31, 2024. Filed Mar 27, 2025.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2024 · Filed Mar 27, 2025
LTRN$0.46-22.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets – December 31, 2024 and 2023
Consolidated Balance Sheets
| December 31, | ||
|---|---|---|
| 2024 | 2023 | |
| CURRENT ASSETS | ||
| Cash and cash equivalents | $7,511,079 | $21,937,749 |
| Marketable securities | 16,501,984 | 19,364,923 |
| Prepaid expenses & other current assets | 1,234,566 | 2,038,653 |
| Total current assets | 25,247,629 | 43,341,325 |
| Property and equipment, net | 47,440 | 52,127 |
| Operating lease right-of-use assets | 239,985 | 228,295 |
| Other assets | 36,738 | 25,869 |
| TOTAL ASSETS | $25,571,792 | $43,647,616 |
| CURRENT LIABILITIES | ||
| Accounts payable and accrued expenses | $4,140,361 | $2,505,211 |
| Operating lease liabilities, current | 190,814 | 172,975 |
| Total current liabilities | 4,331,175 | 2,678,186 |
| Operating lease liabilities, net of current portion | 52,843 | 61,496 |
| TOTAL LIABILITIES | 4,384,018 | 2,739,682 |
| COMMITMENTS AND CONTINGENCIES (NOTE 4) | - | - |
| STOCKHOLDERS’ EQUITY | ||
| Preferred Stock (1,000,000 authorized at December 31, 2024 and December 31, 2023; $.0001 par value) (Zero shares issued and outstanding at December 31, 2024 and December 31, 2023) | - | - |
| Common Stock (25,000,000 authorized at December 31, 2024 and December 31, 2023; $.0001 par value) (10,784,725 shares issued and outstanding at December 31, 2024; 10,721,192 shares issued and outstanding at December 31, 2023) | 1,078 | 1,072 |
| Additional paid-in capital | 97,058,323 | 96,258,726 |
| Accumulated other comprehensive income (loss) | 153,990 | (107,460) |
| Accumulated deficit | (76,025,617) | (55,244,404) |
| Total stockholders’ equity | 21,187,774 | 40,907,934 |
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $25,571,792 | $43,647,616 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.